Clinical trials: Malaria, Uncomplicated
Malaria
Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.
The objective of the study is to assess the efficacy and safety of SAR97276A in severe malaria in pediatric patients. Before treating pediatric patients with severe malaria, the efficacy and safety of SAR97276A will be first…
- Trial name
- NCT00739206
- Testing
- SAR97276A
- Where
- 4 sites in Benin, Burkina Faso and 2 more
- Volunteers
- 113 people
- Sponsor
- Sanofi
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Infection
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms.
- Trial name
- AL3vs5 (NCT02020330)
- Testing
- Artemether-lumefantrine 3 days, Artemether-lumefantrine 5 days
- Where
- Burma
- Volunteers
- 150 people
- Sponsor
- University of Oxford
P. Falciparum Malaria
Compare the Effectiveness Between Existing Treatment and New Treatment
In camps for displaced persons located along the Thai-Myanmar border, mefloquine and artesunate combination therapy has been used since 1992.
- Trial name
- RDM (NCT01640587)
- Testing
- Mefloquine+Artesunate, Dihydroartemisinin-Piperaquine
- Where
- Thailand
- Volunteers
- 76 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Infection
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To determine whether a single dose combination of OZ439 (Artefenomel)/FQ (Ferroquine) was an efficacious treatment for uncomplicated Plasmodium falciparum malaria in adults and children.
- Trial name
- FALCI (NCT02497612)
- Testing
- Ferroquine SSR97193, Artefenomel
- Where
- 12 sites in Benin, Burkina Faso and 5 more
- Volunteers
- 377 people
- Sponsor
- Sanofi
Malaria
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
This non-interventional qualitative study will examine factors that influence the adoption of a novel malaria treatment in Côte d'Ivoire, Ghana, and Rwanda.
- Trial name
- NCT07896746
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Malaria
Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
Despite all efforts, malaria remains a public health concern, in particular in the Democratic Republic of the Congo (DRC). The National Malaria Control program recommends artemisinin-based combination treatments (ACTs), in…
- Trial name
- TET2020 (NCT04618523)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,117 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Uncomplicated Plasmodium Falciparum Malaria
Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo
Malaria remains a public health concern, despite efforts that are invested in the disease control. The Democratic Republic of the Congo (DRC) is one of the most affected countries in Sub Saharan Africa.
- Trial name
- TES2022 (NCT06076213)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 7 sites in Democratic Republic of the Congo
- Volunteers
- 1,260 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Uncomplicated Falciparum Malaria
Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria
Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world.
- Trial name
- ACT (NCT00902811)
- Testing
- AM(FDC), AM(LT), AL
- Where
- 4 sites in Burma
- Volunteers
- 600 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine + amodiaquine (AL+AQ) and artesunate- mefloquine+piperaquine (AS-MQ+PPQ) with…
- Trial name
- DeTACT-ASIA (NCT03939104)
- Testing
- Artemether-lumefantrine+amodiaquine, Artesunate-mefloquine+piperaquine
- Where
- 3 sites in Bangladesh, Cambodia
- Volunteers
- 103 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
The primary objective of the study was to determine PCR corrected cure-rates up to day 42 in children with uncomplicated malaria, treated with either Artesunate + Amodiaquine or Coartem®.
- Trial name
- AcoI (NCT03764527)
- Testing
- Artemether-lumefantrine, Coadministered Artesunate plus Amodiaquine
- Volunteers
- 408 people
- Sponsor
- Professor Anders Björkman
Severe Malaria, Uncomplicated Malaria
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion…
- Conditions
- Severe Malaria, Uncomplicated Malaria, Asyptomatic Plasmodium Infection
- Trial name
- IMMETASEX (NCT06064591)
- Where
- 3 sites in Belgium, Burkina Faso and 1 more
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Falciparum, HIV Infections
Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania
As HIV/AIDS is spreading in malaria-endemic countries, many patients here will need concomitant treatment for both infections. Effective combination treatments are available for both malaria (artemisinin-based combination…
- Trial name
- InterACT (NCT00885287)
- Testing
- Artemether-lumefantrine (AL)
- Where
- Tanzania
- Volunteers
- 830 people
- Sponsor
- University of Copenhagen
Uncomplicated Plasmodium Knowlesi Malaria
P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine
Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however this has not been tested systematically and there are no current…
- Trial name
- ACT KNOW (NCT01708876)
- Testing
- Artesunate-mefloquine, Chloroquine, Primaquine
- Where
- 3 sites in Malaysia
- Volunteers
- 250 people
- Sponsor
- Menzies School of Health Research
Acute Falciparum Malaria
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
Background: Malaria is an illness caused by a parasite that enters people s bodies when a mosquito bites them. It can cause fevers, headaches, body aches, and weakness. If not treated, it can make some people very ill.
- Trial name
- NCT02612545
- Testing
- Dihydroartemisinin-piperaquine (DHA-PPQ), Mefloquine (MQ)
- Where
- Cambodia
- Volunteers
- 216 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum, Malaria, Falciparum
Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO
Phase IV, single center, 2 arms randomized controlled, open label study. Study will be conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics and efficacy of ARCO.
- Trial name
- NCT01930331
- Testing
- artemisinin/naphthoquine, dihydroartemisinin/piperaquine phosphate
- Where
- Tanzania
- Volunteers
- 60 people
- Sponsor
- Ifakara Health Institute
Acute Uncomplicated Plasmodium Falciparum Malaria
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
This study was designed to determine the most effective and tolerable dose at the shortest dosing regimen of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in…
- Trial name
- NCT03167242
- Testing
- KAF156, Coartem, Lumefantrine Solid Dispersion Formulation
- Where
- 11 sites in Burkina Faso, Gabon and 7 more
- Volunteers
- 524 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
This is a pilot, double-blind, randomized, parallel-group, placebo-control, exploratory study to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride (5-ALA HCl) and sodium ferrous citrate (SFC) added on…
- Trial name
- NCT04020653
- Testing
- 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD, Sodium ferrous citrate (SFC) 472 mg QD, Artemisinin-based combination (ACT)
- Sponsor
- Neopharma Japan Co., Ltd.
Malaria
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be…
- Trial name
- NCT01361269
- Testing
- Fosmidomycin and clindamycin
- Where
- Gabon
- Volunteers
- 100 people
- Sponsor
- Zentopharm GmbH
Malaria
Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria
Primary Objective: To assess the antiparasitic activity of intramuscular (IM) SAR97276A based on parasite reduction ratio at 72 hours in pediatric patients with uncomplicated malaria Secondary Objectives: To assess the evolution…
- Trial name
- NCT01445938
- Testing
- SAR97276A, arthemeter + lumefantrine (ACTs)
- Where
- 4 sites in Benin, Burkina Faso and 2 more
- Volunteers
- 20 people
- Sponsor
- Sanofi